PMID- 11570586
OWN - NLM
STAT- MEDLINE
DCOM- 20011004
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 50
IP  - 6
DP  - 2001 Aug
TI  - The generation of anti-tumoral cells using dentritic cells from the peripheral 
      bloood of patients with malignant brain tumors.
PG  - 321-7
AB  - Dendritic cells (DCs) can be the principal initiators of antigen-specific immune 
      responses. We analyzed the in vitro-responses against brain tumor cells using DCs 
      from the peripheral blood of patients with brain tumors. Peripheral blood 
      mononuclear cells (PBMC) were obtained from 19 patients with malignant brain 
      tumors: 12 metastatic brain tumors of lung adenocarcinoma, 7 high-grade 
      astrocytomas. PBMC were cultured with 100 ng/ml of GM-CSF and 10 ng/ml of IL-4 
      for 5 7 days in order to produce mature DCs. The autologous tumor lysate (5 
      mg/ml, containing 1 x 10(6) cells) was then added to the cultured DCs. Using the 
      DCs generated by these treatments, we assessed the changes that occurred in their 
      immune responses against brain tumor via 51Cr-release and lymphocyte 
      proliferation assays. We found that the matured DCs displayed the typical surface 
      phenotype of CD3+, CD45+, CD80+ and CD86+. After the pulsation treatment with 
      tumor lysate, DCs were found to have strong cytotoxic T lymphocyte activity, 
      showing 42.5+12.7% killing of autologous tumor cells. We also found an 
      enhancement of allogeneic T cell proliferation after pulsing the DC with tumor 
      lysate. These data support the efficacy of DC-based immunotherapy for patients 
      with malignant brain tumors.
FAU - Yoshida, S
AU  - Yoshida S
AD  - Department of Neurosurgery, Niigata Cancer Center Hospital, Japan. 
      brain@niigata-cc.niigata.niigata.jp
FAU - Morii, K
AU  - Morii K
FAU - Watanabe, M
AU  - Watanabe M
FAU - Saito, T
AU  - Saito T
FAU - Yamamoto, K
AU  - Yamamoto K
FAU - Tanaka, R
AU  - Tanaka R
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Adenocarcinoma/blood/*immunology/secondary
MH  - Astrocytoma/blood/*immunology
MH  - Brain Neoplasms/blood/*immunology/secondary
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/cytology/*immunology
MH  - Flow Cytometry
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Interleukin-4/pharmacology
MH  - Lung Neoplasms/pathology
MH  - Lymphocyte Activation/immunology
MH  - T-Lymphocytes/cytology/immunology
MH  - Tumor Necrosis Factor-alpha/pharmacology
PMC - PMC11036844
EDAT- 2001/09/26 10:00
MHDA- 2001/10/05 10:01
PMCR- 2001/08/01
CRDT- 2001/09/26 10:00
PHST- 2001/09/26 10:00 [pubmed]
PHST- 2001/10/05 10:01 [medline]
PHST- 2001/09/26 10:00 [entrez]
PHST- 2001/08/01 00:00 [pmc-release]
AID - 10500321.262 [pii]
AID - 10.1007/s002620100201 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2001 Aug;50(6):321-7. doi: 10.1007/s002620100201.